Ask Warren

Neuromeka

348340 · KOSDAQ · ₩348340 · 뉴로메카

₩16,470▼ ₩740 (4.30%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩2.8B₩3B₩7.9B₩4.5B₩3.4B₩3.2B₩8.1B₩6.2B
Cost of sales₩2.2B₩2.3B₩6.4B₩3.7B₩2.8B₩2.6B₩7.3B₩5.3B
Gross profit₩597M₩675M₩1.5B₩734M₩650M₩579M₩772M₩914M
Operating income−₩5.3B−₩4.3B−₩3.5B−₩3.2B−₩4.2B−₩4B−₩3.8B−₩5.7B
Net income₩21B−₩26B−₩18B₩331M₩2.7B−₩7.3B−₩10B−₩6.6B
Net income to shareholders−₩4.5B−₩26B−₩5.7B−₩4.3B−₩4.6B−₩7.3B−₩4B−₩6.8B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩92B₩83B₩91B₩92B₩95B₩95B₩95B₩83B
Current assets₩33B₩30B₩38B₩38B₩40B₩42B₩42B₩36B
Cash and equivalents₩10B₩6.5B₩17B₩14B₩19B₩13B₩19B₩8.7B
Total liabilities₩55B₩42B₩77B₩78B₩76B₩72B₩84B₩71B
Current liabilities₩45B₩34B₩69B₩49B₩46B₩46B₩58B₩49B
Borrowings₩48B₩13B₩31B₩54B₩53B₩48B₩53B₩43B
Total equity₩37B₩41B₩14B₩14B₩18B₩23B₩11B₩12B
Shareholders' equity₩36B₩40B₩14B₩14B₩18B₩23B₩11B₩12B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩2.9B−₩12B₩219M−₩3.6B₩3.1B−₩11B−₩1.9B−₩8.9B
Capital spending₩4.1B₩534M₩136M₩447M₩1.9B₩679M₩5.9B₩6B
Free cash flow−₩7B−₩13B₩82M−₩4B₩1.2B−₩12B−₩7.8B−₩15B

Consolidated where available. Amounts in won.

Also known as: Neuromeka / 뉴로메카 / 348340 / KRX:348340

Source: KRX statistical information